Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion
Sobi launches Ravicti in Europe and advances the care for patients with Urea Cycle Disorders
Swedish Orphan Biovitrum has gained reimbursement for Ravicti, a new therapy option for the treatment of patients with Urea Cycle
EMA grants accelerated assessment for Shire’s Lanadelumab being evaluated for the prevention of attacks in Hereditary Angioedema patients aged 12 years and older
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for
Novo Nordisk files for regulatory approval in the US and the EU for treatment of haemophilia A
Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing
BASF reports 26% EBIT increase in chemical business
BASF has reported financial results for the year 2017. The company said that following a successful 2017 business year, BASF
Boehringer Ingelheim doubles funding to 250 M€ for its corporate venture fund
Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million.
Premaitha signs new partner to offer NIPT solution in East Asia
Premaitha Health has signed an agreement with a new laboratory partner to offer an NIPT screening solution in a new East Asian territory for Premaitha.
Sanofi appoints new EVP Diabetes & Cardiovascular
Sanofi has appointed Stefan Oelrich as Executive Vice President Diabetes & Cardiovascular (DCV), effectively immediately.
Novartis’s Alcon introduces new innovations in cataract surgery at ESCRS 2017 annual congress
Alcon, a division of Novartis, will introduce Clareon, the intraocular lens (IOL) with the most advanced optic material available in an automated, disposable, pre-loaded delivery system, at the XXXV European Society of Cataract & Refractive Surgeons (ESCRS) congress taking place October 7 – 11 in Lisbon, Portugal.
Novartis and UC Berkeley collaborate to tackle ‘undruggable’ disease targets
Novartis has joined forces with researchers from the University of California, Berkeley, to develop new technologies for the discovery of next-generation therapeutics, pursuing the vast number of disease targets in cancer and other illnesses that have eluded traditional small-molecule compounds and are considered “undruggable.”